...
首页> 外文期刊>International journal of pediatric otorhinolaryngology >Intranasal phenylephrine-surfactant treatment is not beneficial in otitis media with effusion.
【24h】

Intranasal phenylephrine-surfactant treatment is not beneficial in otitis media with effusion.

机译:鼻内苯肾上腺素表面活性剂治疗在积液性中耳炎中无益。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Otitis media is the most common reason for non-well-child visits to the primary care physician. Various treatments are in use to try to ameliorate the pain arising from Eustachian tube (ET) dysfunction. One such treatment is topical phenylephrine spray, despite clinical evidence disputing its use. Previous research by this laboratory has demonstrated the beneficial effect of topical surfactant treatment in reducing ET opening pressure, allowing the tube to open. This study is designed to test the effectiveness of topical phenylephrine, delivered with surfactant, in reducing days of effusion in OME, in an animal model. METHODS: OME was generated by injecting Klebsiella pneumoniae lipopolysaccharide into the right bullae of 28 gerbils. After frank OME resulted, the animals were divided into four groups. Group 1 received no treatment or propellant spray alone (placebo). Group 2 received intranasal surfactant spray once daily. Group 3 received intranasal surfactant-phenylephrine spray once daily. Group 4 received intranasal surfactant-phenylephrine spray twice daily. All animals were evaluated on a daily basis by both otomicroscopy and tympanometry, and treatment was ceased when the ear returned to normal appearance. Evaluations were continued for a total of 30 days. Chi-squared analysis with significance set at .05 was performed. RESULTS: In the untreated and placebo groups, middle ear effusion resolved at 16.25 days by otomicroscopy and 28.26 days by tympanometry. In Group 2 (surfactant alone), effusion resolved at 10.57 days and 15.71 days, respectively. In Group 3 (surfactant-phenylephrine once daily), effusion resolved at 15.67 days and 28.33 days. In Group 4 (surfactant-phenylephrine twice daily), effusion resolved at 18.67 days and 28.33 days. These results were statistically significant. CONCLUSIONS: Intranasal phenylephrine-surfactant treatment is shown to be at least ineffective, and possibly detrimental, in the resolution of OME, in this animal model. The hypothesis is that surfactant potentiates the drying effect of phenylephrine at the ET by allowing it to get to the ET more easily; in addition, the drying effect of phenylephrine prevents full surfactant action. We believe that these results can be extrapolated to humans and that phenylephrine should be avoided in these cases.
机译:背景:中耳炎是非健康儿童就诊初级保健医生的最常见原因。为了减轻因咽鼓管(ET)功能障碍引起的疼痛,正在使用各种治疗方法。尽管临床证据反对使用脱氧肾上腺素喷剂,但仍是此类治疗之一。该实验室先前的研究表明,局部表面活性剂处理在降低ET打开压力,使管子打开方面具有有益作用。这项研究旨在在动物模型中测试与表面活性剂一起递送的局部去氧肾上腺素在减少OME中积液天数方面的有效性。方法:通过将肺炎克雷伯菌(Klebsiella pneumoniae)脂多糖注射到28只沙鼠的右大疱中来产生OME。坦率的OME结果后,将动物分为四组。第1组未接受任何治疗或单独使用推进剂喷雾剂(安慰剂)。第2组每天接受一次鼻内表面活性剂喷雾。第3组每天接受一次鼻内表面活性剂-去氧肾上腺素喷雾。第4组每天两次接受鼻内表面活性剂-去氧肾上腺素喷雾。每天通过耳镜和鼓室分析法评估所有动物,并在耳朵恢复正常外观后停止治疗。评估持续了总共30天。进行卡方分析,显着性设置为.05。结果:未治疗组和安慰剂组中,中耳积液在耳镜下分别在16.25天和28.26天处消失。在第2组(仅表面活性剂)中,积液分别在10.57天和15.71天消失。在第3组中(每天一次表面活性剂去氧肾上腺素),积液在15.67天和28.33天消失。在第4组(表面活性剂-去氧肾上腺素每天两次)中,积液在18.67天和28.33天消失。这些结果具有统计学意义。结论:在该动物模型中,鼻内去氧肾上腺素表面活性剂治疗对OME的治疗显示出至少无效,并且可能有害。假设是表面活性剂通过使苯肾上腺素更容易到达ET来增强其在ET上的干燥效果。此外,去氧肾上腺素的干燥作用阻止了表面活性剂的全部作用。我们认为,这些结果可以推断给人类,在这些情况下应避免使用去氧肾上腺素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号